Ischemia

3
Pipeline Programs
5
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Roche
RocheSTAVANGER NORWAY, Norway
1 program
1
beta-epoietinPhase 31 trial
Active Trials
NCT01450878Terminated6Est. Mar 2013
Lantheus Medical Imaging
1 program
1
BMS747158Phase 21 trial
Active Trials
NCT00849108CompletedEst. Jun 2010
Bristol Myers Squibb
1 program
1
ClopidogrelPhase 2
Abbott
AbbottABBOTT PARK, IL
1 program
St. Jude Medical Pressure WireN/A1 trial
Active Trials
NCT02648230Completed74Est. Dec 2016
GS
Gilead SciencesFOSTER CITY, CA
1 program
ambrisentanN/A1 trial
Active Trials
NCT01072669Completed20Est. Dec 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Rochebeta-epoietin
Lantheus Medical ImagingBMS747158
AbbottSt. Jude Medical Pressure Wire
Gilead Sciencesambrisentan

Clinical Trials (4)

Total enrollment: 100 patients across 4 trials

NCT01450878Rochebeta-epoietin

Renal Graft Function After Treatment With Erythropoietin (EPO)

Start: Dec 2011Est. completion: Mar 20136 patients
Phase 3Terminated
NCT00849108Lantheus Medical ImagingBMS747158

Development of 1-Day Rest/Stress Cardiac PET Perfusion Imaging Protocol of BMS747158

Start: Jan 2009Est. completion: Jun 2010
Phase 2Completed
NCT02648230AbbottSt. Jude Medical Pressure Wire

PrEssure wiRe Compared to Microcatheter-based Sensing Technology For the Evaluation of FFR Measurements

Start: Dec 2015Est. completion: Dec 201674 patients
N/ACompleted
NCT01072669Gilead Sciencesambrisentan

Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet

Start: Feb 2010Est. completion: Dec 201020 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
5 companies competing in this space